Skip to main content

Advertisement

SpringerLink
Log in

Linking the septin expression with carcinogenesis

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The septin is a conserved GTP binding protein family which is involved in multiple cellular processes. Many evidences have indicated that some septins were abnormally expressed in certain kinds of tumors and the altered expressions were related to the process of carcinogenesis. To better understand the relationship between septins and cancer, we compared the expression of 14 human septin family members in 35 kinds of tumor types with their normal counterparts using the publicly available ONCOMINE microarray database. We found altered expression of most septin members in many kinds of tumors. Significantly, SEPT2, SEPT8, SEPT9, SEPT11 were consistently up-regulated, and SEPT4, SEPT10 were down-regulated in most cancer types investigated. Furthermore, the abnormal expressions were also in accordance with the tumor malignances or prognosis of corresponding cancer patients. These findings have contributed to the view that septins may belong to a kind of cancer critical genes. More septins might act as potential oncogenes or tumor suppressor genes in cancer development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Field CM, Kellogg D (1999) Septins: cytoskeletal polymers or signalling GTPases? Trends Cell Biol 9:387–394

    Article  CAS  PubMed  Google Scholar 

  2. Hartwell LH (1971) Genetic control of cell division cycle in yeast.4. genes controlling bud emergence and cytokinesis. Exp Cell Res 69:265

    Article  CAS  PubMed  Google Scholar 

  3. Kinoshita M, Kumar S, Mizoguchi A, Ide C, Kinoshita A, Haraguchi T et al (1997) Nedd5, a mammalian septin, is a novel cytoskeletal component interacting with actin-based structures. Genes Dev 11:1535–1547

    Article  CAS  PubMed  Google Scholar 

  4. Weirich CS, Erzberger JP, Barral Y (2008) The septin family of GTPases: architecture and dynamics. Nat Rev Mol Cell Biol 9:478–489

    Article  CAS  PubMed  Google Scholar 

  5. Hsu SC, Hazuka CD, Roth R, Foletti DL, Heuser J, Scheller RH (1998) Subunit composition, protein interactions, and structures of the mammalian brain sec6/8 complex and septin filaments. Neuron 20:1111–1122

    Article  CAS  PubMed  Google Scholar 

  6. Beites CL, Xie H, Bowser R, Trimble WS (1999) The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat Neurosci 2:434–439

    Article  CAS  PubMed  Google Scholar 

  7. Larisch S, Yi Y, Lotan R, Kerner H, Eimerl S, Tony Parks W et al (2000) A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol 2:915–921

    Article  CAS  PubMed  Google Scholar 

  8. Russell SEH, Hall PA (2005) Do septins have a role in cancer? Br J Cancer 93:499–503

    Article  CAS  PubMed  Google Scholar 

  9. Hall PA, Russell SE (2004) The pathobiology of the septin gene family. J Pathol 204:489–505

    Article  CAS  PubMed  Google Scholar 

  10. Taki T, Ohnishi H, Shinohara K, Sako M, Bessho F, Yanagisawa M et al (1999) AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25). Cancer Res 59:4261–4265

    CAS  PubMed  Google Scholar 

  11. Ono R, Taki T, Taketani T, Kawaguchi H, Taniwaki M, Okamura T et al (2002) SEPTIN6, a human homologue to mouse SEPTIN6, is fused to MLL in infant acute myeloid leukemia with complex chromosomal abnormalities involving 11q23 and xq24. Cancer Res 62:333–337

    CAS  PubMed  Google Scholar 

  12. Osaka M, Rowley JD, Zeleznik-Le NJ (1999) MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci USA 96:6428–6433

    Article  CAS  PubMed  Google Scholar 

  13. Kojima K, Sakai I, Hasegawa A, Niiya H, Azuma T, Matsuo Y et al (2004) FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23). Leukemia 18:998–1005

    Article  CAS  PubMed  Google Scholar 

  14. Kim DS, Hubbard SL, Peraud A, Salhia B, Sakai K, Rutka JT (2004) Analysis of mammalian septin expression in human malignant brain tumors. Neoplasia 6:168–178

    Article  CAS  PubMed  Google Scholar 

  15. Tanaka M, Kijima H, Itoh J, Matsuda T, Tanaka T (2002) Impaired expression of a human septin family gene Bradeion inhibits the growth and tumorigenesis of colorectal cancer in vitro and in vivo. Cancer Gene Ther 9:483–488

    Article  CAS  PubMed  Google Scholar 

  16. Larisch S, Yi YS, Lotan R, Kerner H, Eimerl S, Parks WT et al (2000) A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif. Nat Cell Biol 2:915–921

    Article  CAS  PubMed  Google Scholar 

  17. Gottfried Y, Rotem A, Lotan R, Steller H, Larisch S (2004) The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. EMBO J 23:1627–1635

    Article  CAS  PubMed  Google Scholar 

  18. Elhasid R, Sahar D, Merling A, Zivony Y, Rotem A, Ben-Arush M et al (2004) Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients. Oncogene 23:5468–5475

    Article  CAS  PubMed  Google Scholar 

  19. Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM et al (2000) Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res 60:4729–4734

    CAS  PubMed  Google Scholar 

  20. Kalikin LM, Sims HL, Petty EM (2000) Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors. Genomics 63:165–172

    Article  CAS  PubMed  Google Scholar 

  21. Scott M, Hyland PL, McGregor G, Hillan KJ, Russell SEH, Hall PA (2005) Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours. Oncogene 24:4688–4700

    Article  CAS  PubMed  Google Scholar 

  22. Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM (2007) High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Res 67:8554–8564

    Article  CAS  PubMed  Google Scholar 

  23. Gonzalez ME, Makarova O, Peterson EA, Privette LM, Petty EM (2009) Up-regulation of SEPT9_v1 stabilizes c-Jun-N-Terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cell Signal 21:477–487

    Article  CAS  PubMed  Google Scholar 

  24. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu JJ, Briggs BB et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166–180

    Article  CAS  PubMed  Google Scholar 

  25. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6:1–6

    CAS  PubMed  Google Scholar 

  26. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173

    Article  CAS  PubMed  Google Scholar 

  27. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF et al (2003) Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22:4918–4923

    Article  CAS  PubMed  Google Scholar 

  28. Kreike B, Halfwerk H, Kristel P, Glas A, Peterse H, Bartelink H et al (2006) Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 12:5705–5712

    Article  CAS  PubMed  Google Scholar 

  29. van de Vijver MJ, He YD, van‘t Veer LJ, Dai H, Hart AAM, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009

    Article  PubMed  Google Scholar 

  30. Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T et al (2004) Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 23:5360–5370

    Article  CAS  PubMed  Google Scholar 

  31. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M et al (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45:938–947

    Article  CAS  PubMed  Google Scholar 

  32. Cromer A, Carles A, Millon R, Ganguli G, Chalmel F, Lemaire F et al (2004) Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23:2484–2498

    Article  CAS  PubMed  Google Scholar 

  33. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313–325

    Article  CAS  PubMed  Google Scholar 

  34. Freije WA, Castro-Vargas FE, Fang ZX, Horvath S, Cloughesy T, Liau LM et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503–6510

    Article  CAS  PubMed  Google Scholar 

  35. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159–2169

    Article  CAS  PubMed  Google Scholar 

  36. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J et al (2006) Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res 12:4533–4544

    Article  CAS  PubMed  Google Scholar 

  37. Larsen JE, Pavey SJ, Passmore LH, Bowman R, Clarke BE, Hayward NK et al (2007) Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 28:760–766

    Article  CAS  PubMed  Google Scholar 

  38. Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SGD, Segraves R et al (2006) Regional copy number-independent deregulation of transcription in cancer. Nat Genet 38:1386–1396

    Article  CAS  PubMed  Google Scholar 

  39. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272

    Article  CAS  PubMed  Google Scholar 

  40. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 66:1354–1362

    Article  CAS  PubMed  Google Scholar 

  41. Nanni S, Priolo C, Grasselli A, D’Eletto M, Merola R, Moretti F et al (2006) Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res 4:79–92

    Article  CAS  PubMed  Google Scholar 

  42. Segal NH, Pavlidis P, Noble WS, Antonescu CR, Viale A, Wesley UV et al (2003) Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol 21:1775–1781

    Article  CAS  PubMed  Google Scholar 

  43. Kinoshita M (2006) Diversity of septin scaffolds. Curr Opin Cell Biol 18:54–60

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National 973 Program and the National Natural Science Foundation of China.

Author information

Authors and Affiliations

  1. State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, 220 Handan Road, Shanghai, 200433, People’s Republic of China

    Ming Liu, Suqin Shen, Fang Chen, Wenbo Yu & Long Yu

Authors
  1. Ming Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suqin Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenbo Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Long Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Long Yu.

Electronic supplementary material

Below is the link to the electronic supplementary material.

11033_2010_9_MOESM1_ESM.tif

Supplementary material 1 (TIFF 542 kb) Supplementary Fig. S1 Over-expression of SEPT2 in 11 cancer types compared to their normal counterparts. Column 1–11 represent the over-expression of SEPT2 in brain tumors, breast cancer, cervix cancer, gastric cancer, head and neck cancer, liver cancer, melanoma, mesothelioma, myeloma, pancreas cancer, and salivary gland cancer respectively

11033_2010_9_MOESM2_ESM.tif

Supplementary material 2 (TIFF 517 kb) Supplementary Fig. S2 Over-expression of SEPT8 in 12 cancer types compared to their normal counterparts. Column 1–12 represent the over-expression of SEPT8 in adrenal cancer, bladder cancer, leukemia, liver cancer, lung cancer, lymphoma, mesothelioma, myeloma, pancreas cancer, renal cancer, salivary gland cancer and seminoma

11033_2010_9_MOESM3_ESM.tif

Supplementary material 3 (TIFF 573 kb) Supplementary Fig. S3 Over-expression of SEPT9 in 15 cancer types compared to their normal counterparts. Column 1–15 represent the over-expression of SEPT9 in brain tumors, breast cancer, esophagus cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, mesothelioma, myeloma, pancreas cancer, renal cancer, salivary gland cancer and seminoma

11033_2010_9_MOESM4_ESM.tif

Supplementary material 4 (TIFF 727 kb) Supplementary Fig. S4 Over-expression of SEPT11 in 12 cancer types compared to their normal counterparts. Column 1–12 represent the over-expression of SEPT11 in brain tumors, breast cancer, cervix cancer, esophagus cancer, head and neck cancer, leukemia, melanoma, ovarian cancer, pancreas cancer, prostate cancer, renal cancer and seminoma

11033_2010_9_MOESM5_ESM.tif

Supplementary material 5 (TIFF 516 kb) Supplementary Fig. S5 Down-regulation of SEPT4 in 11 cancer types compared to their normal counterparts. Column 1–11 represent the down-regulation of SEPT11 in adrenal cancer, bladder cancer, brain tumors, breast cancer, cervix cancer, liver cancer, lung cancer, melanoma, ovarian cance, pancreas cancer and seminoma

11033_2010_9_MOESM6_ESM.tif

Supplementary material 6 (TIFF 553 kb) Supplementary Fig. S6 Down-regulation of SEPT10 in 11 cancer types compared to their normal counterparts. Column 1–11 represent the down-regulation of SEPT11 in bladder cancer, breast cancer, head and neck carcinoma, liver cancer, lung cancer, melanoma, ovarian, pancreas, prostate, seminoma and testis tumor

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, M., Shen, S., Chen, F. et al. Linking the septin expression with carcinogenesis. Mol Biol Rep 37, 3601–3608 (2010). https://doi.org/10.1007/s11033-010-0009-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-010-0009-2

Keywords

Search

Navigation